Newsletter Signup – Under Article / In Page
“*” indicates required fields
In June 2025, Eli Lilly announced it would acquire Verve Therapeutics in a deal valued at up to $1.3 billion, centered on a one-time gene-editing therapy, VERVE-102,…
“*” indicates required fields
In June 2025, Eli Lilly announced it would acquire Verve Therapeutics in a deal valued at up to $1.3 billion, centered on a one-time gene-editing therapy, VERVE-102,…